Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/06/14 | $1,000,000 | Seed |
Dolby Family Ventures | undisclosed |
| 05/31/18 | $76,000,000 | Series B |
Breakout Ventures Dolby Family Ventures EPIQ Capital Group Huizenga Capital Management Lamond Family Pfizer Venture Investments RSL Investments Takeda Ventures Verily Life Sciences Vulcan Capital | undisclosed |
